Friday, August 14, 2026
Knowledge FilesExploreSearch
Via News
Facts you can rely on·101 entities·4,806 sourced facts
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

Johnson & Johnson Cardiac Trial Data Refines Impella Role In MedTech Story

View original at finance.yahoo.com
Johnson & Johnson Cardiac Trial Data Refines Impella Role In MedTech Story Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Johnson & Johnson now has randomized data that can anchor future studies focused on narrower patient groups and on combinations with adjunct therapies that aim to reduce reperfusion injury

    60% confidence

  • The trial clarifies that routine pre procedure Impella use purely for infarct size reduction is not supported by this dataset

    60% confidence

  • The STEMI DTU trial showed no reduction in heart muscle damage from Impella CP use before coronary intervention in heart attack patients

    60% confidence

  • The results are expected to guide future research on device use and potential adjunct pharmacotherapies

    60% confidence